SinoMab BioScience Ltd
Buy, Hold or Sell?

Let's analyse Sinomab together

Penke I guess you are interested in SinoMab BioScience Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of SinoMab BioScience Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about SinoMab BioScience Ltd

I send you an email if I find something interesting about SinoMab BioScience Ltd.

Quick analysis of Sinomab (30 sec.)

What can you expect buying and holding a share of Sinomab? (30 sec.)

How much money do you get?

HK$0.00

When do you have the money?

1 year

How often do you get paid?

0.0%

What is your share worth?

Current worth

HK$0.47

Expected worth in 1 year

HK$-0.16

How sure are you?

33.3%

+ What do you gain per year?

Total Gains per Share

HK$-0.63

Return On Investment

-33.1%

For what price can you sell your share?

Current Price per Share

HK$1.89

Expected price per share

HK$1.81 - HK$1.91

How sure are you?

50%

1. Valuation of Sinomab (5 min.)

Live pricePrice per Share (EOD)

HK$1.89

Book Value per Share

HK$0.47

Intrinsic Value Per Share

HK$-4.32 - HK$-3.79

Total Value Per Share

HK$-3.85 - HK$-3.32

My calculation of the intrinsic value of Sinomab is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 5Y: (HK$-0.20) 3Y: (HK$-0.24)
The change per quarter (trend) of the Free Cash Flow Per Share is 5Y: (HK$-0.07) 3Y: (HK$-0.05)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	HK$-0.29	HK$-0.24	HK$-0.31 - HK$-0.25
2	HK$-0.63	HK$-0.52	HK$-0.38 - HK$-0.30
3	HK$-1.01	HK$-0.83	HK$-0.45 - HK$-0.34
4	HK$-1.42	HK$-1.18	HK$-0.52 - HK$-0.39
5	HK$-1.86	HK$-1.55	HK$-0.59 - HK$-0.43
6	HK$-2.32	HK$-1.95	HK$-0.65 - HK$-0.48
7	HK$-2.80	HK$-2.38	HK$-0.72 - HK$-0.52
8	HK$-3.29	HK$-2.83	HK$-0.79 - HK$-0.57
9	HK$-3.80	HK$-3.30	HK$-0.86 - HK$-0.62
10	HK$-4.32	HK$-3.79	HK$-0.93 - HK$-0.66

2. Growth of Sinomab (5 min.)

Is Sinomab growing?

	Current year	Previous year	Grow	Grow %
How rich?	$65m	$86.8m	-$21.7m	-33.5%

How much money is Sinomab making?

	Current year	Previous year	Grow	Grow %
Making money	-$36.2m	-$36.8m	$515.3k	1.4%
Net Profit Margin	0.0%	-1,112.2%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Sinomab (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#444 / 1019

Most Revenue
#913 / 1019

Most Profit
#838 / 1019

Most Efficient
#358 / 1019

What can you expect buying and holding a share of Sinomab? (5 min.)

Welcome investor! Sinomab's management wants to use your money to grow the business. In return you get a share of Sinomab.

What can you expect buying and holding a share of Sinomab?

First you should know what it really means to hold a share of Sinomab. And how you can make/lose money.

Speculation

The Price per Share of Sinomab is HK$1.89. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Sinomab.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sinomab, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$0.47. Based on the TTM, the Book Value Change Per Share is HK$-0.16 per quarter. Based on the YOY, the Book Value Change Per Share is HK$-0.28 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Sinomab.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	HK$	% of Price per Share	HK$	% of Price per Share	HK$	% of Price per Share	HK$	% of Price per Share	HK$	% of Price per Share
Usd Eps	-0.03	-1.8%	-0.03	-1.8%	-0.03	-1.8%	-0.02	-1.3%	-0.02	-1.1%
Usd Book Value Change Per Share	-0.02	-1.1%	-0.02	-1.1%	-0.04	-1.9%	0.01	0.7%	0.01	0.5%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%
Usd Total Gains Per Share	-0.02	-1.1%	-0.02	-1.1%	-0.04	-1.9%	0.01	0.7%	0.01	0.5%
Usd Price Per Share	0.23	-	0.23	-	0.37	-	0.33	-	0.27	-
Price to Earnings Ratio	-6.95	-	-6.95	-	-10.83	-	-14.55	-	-12.12	-
Price-to-Total Gains Ratio	-11.58	-	-11.58	-	-10.18	-	-13.23	-	-13.23	-
Price to Book Ratio	3.88	-	3.88	-	4.59	-	3.39	-	2.83	-
Price-to-Total Gains Ratio	-11.58	-	-11.58	-	-10.18	-	-13.23	-	-13.23	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	0.241353
Number of shares	4143

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.00
Usd Book Value Change Per Share	-0.02	0.01
Usd Total Gains Per Share	-0.02	0.01
Gains per Quarter (4143 shares)	-82.70	54.33
Gains per Year (4143 shares)	-330.79	217.30

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	0	-331	-341	0	217	207
2	0	-662	-672	0	435	424
3	0	-992	-1003	0	652	641
4	0	-1323	-1334	0	869	858
5	0	-1654	-1665	0	1087	1075
6	0	-1985	-1996	0	1304	1292
7	0	-2316	-2327	0	1521	1509
8	0	-2646	-2658	0	1738	1726
9	0	-2977	-2989	0	1956	1943
10	0	-3308	-3320	0	2173	2160

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	0.0	1.0	0.0	0.0%	0.0	3.0	0.0	0.0%	0.0	5.0	0.0	0.0%	0.0	6.0	0.0	0.0%	0.0	6.0	0.0	0.0%
Book Value Change Per Share	0.0	1.0	0.0	0.0%	0.0	3.0	0.0	0.0%	2.0	3.0	0.0	40.0%	2.0	4.0	0.0	33.3%	2.0	4.0	0.0	33.3%
Dividend per Share	0.0	0.0	1.0	0.0%	0.0	0.0	3.0	0.0%	0.0	0.0	5.0	0.0%	0.0	0.0	6.0	0.0%	0.0	0.0	6.0	0.0%
Total Gains per Share	0.0	1.0	0.0	0.0%	0.0	3.0	0.0	0.0%	2.0	3.0	0.0	40.0%	2.0	4.0	0.0	33.3%	2.0	4.0	0.0	33.3%

Fundamentals of Sinomab

About SinoMab BioScience Ltd

https://www.sinomab.com
Biotechnology
0
No.15 Science Park West Avenue, Tai Po, Hong Kong
Google Maps Bing Maps

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. It operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.

Fundamental data was last updated by Penke on 2024-04-16 20:45:06.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry

Liquidity Details

	Compared to previous year	Compared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of SinoMab BioScience Ltd.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Sinomab earns for each $1 of revenue.

Above 10% is considered healthy but always compare Sinomab to the Biotechnology industry mean.
A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of SinoMab BioScience Ltd:

The MRQ is 0.0%. The data is not here.

Trends

Current period		Compared to		+/-
MRQ	-	TTM	-	0.0%
TTM	-	YOY	-1,112.2%	+1,112.2%
TTM	-	5Y	-222.4%	+222.4%
5Y	-222.4%	10Y	-185.4%	-37.1%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-	-197.2%	+197.2%
TTM	-	-210.4%	+210.4%
YOY	-1,112.2%	-279.3%	-832.9%
5Y	-222.4%	-436.8%	+214.4%
10Y	-185.4%	-599.3%	+413.9%

Measures how much net profit Sinomab earns for each $1 of revenue.

Revenue is the amount of profit Sinomab generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Sinomab earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Sinomab to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Sinomab makes more profit. This shows the investor how efficiently Sinomab is operating in general and compared to other companies in the same industry. Sinomab operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Sinomab. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Sinomab is 0.00. This means that Sinomab earned $0.00 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -197.2%.
What is the trend?
The trend is important because it shows you how Sinomab is performing over time. The most recent quarter might be important if Sinomab released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sinomab up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Sinomab with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Sinomab sells assets (profit will increase while costs remain the same).
It won’t show what part of Sinomab is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Sinomab

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Sinomab = -134,096
Total revenue MRQ Sinomab = 1,365
$-134,096 / $1,365 = 0.00 or 0.0%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Sinomab is using its assets to generate profit.

Above 5% is considered healthy but always compare Sinomab to the Biotechnology industry mean.
-28.2% Return on Assets means that Sinomab generated $-0.28 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of SinoMab BioScience Ltd:

The MRQ is -28.2%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -28.2%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-28.2%	TTM	-28.2%	0.0%
TTM	-28.2%	YOY	-27.7%	-0.5%
TTM	-28.2%	5Y	-36.5%	+8.3%
5Y	-36.5%	10Y	-35.3%	-1.1%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-28.2%	-13.6%	-14.6%
TTM	-28.2%	-12.9%	-15.3%
YOY	-27.7%	-11.9%	-15.8%
5Y	-36.5%	-14.2%	-22.3%
10Y	-35.3%	-16.2%	-19.1%

Shows how efficient Sinomab is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Sinomab to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Sinomab is using its resources to generate profit. If the return on assets (-28.2%) from Sinomab are higher than the Biotechnology mean (-13.6%) that means Sinomab is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Sinomab is -28.2%. This means the company generated $-0.28 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.6%.
What is the trend?
The trend is important because it shows you how Sinomab is performing over time. The most recent quarter might be important if Sinomab released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sinomab up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Sinomab

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Sinomab = -134,096
Total assets MRQ (balance sheet) from Sinomab = 907,389
-134,096 / 907,389 = -0.28 or -28.2%

ROA is an important ratio as it will tell you how effectively Sinomab is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Sinomab is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Sinomab to the Biotechnology industry mean.
-55.8% Return on Equity means Sinomab generated $-0.56 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of SinoMab BioScience Ltd:

The MRQ is -55.8%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -55.8%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-55.8%	TTM	-55.8%	0.0%
TTM	-55.8%	YOY	-42.4%	-13.4%
TTM	-55.8%	5Y	-88.0%	+32.2%
5Y	-88.0%	10Y	-73.3%	-14.7%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-55.8%	-17.0%	-38.8%
TTM	-55.8%	-16.1%	-39.7%
YOY	-42.4%	-15.4%	-27.0%
5Y	-88.0%	-20.0%	-68.0%
10Y	-73.3%	-21.1%	-52.2%

Shows how efficient Sinomab is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Sinomab to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Sinomab is -55.8%. This means Sinomab generated $-0.56 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -17.0%.
What is the trend?
The trend is important because it shows you how Sinomab is performing over time. The most recent quarter might be important if Sinomab released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sinomab up to 10 years back (depending if Sinomab existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Sinomab

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Sinomab = -134,096
Shareholders equity (balance sheet) MRQ Sinomab = 406,138
-134,096 / 406,138 = -0.56 or -55.8%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of SinoMab BioScience Ltd.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Sinomab is operating .

Measures how much profit Sinomab makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Sinomab to the Biotechnology industry mean.
An Operating Margin of 0.0% means the company generated $0.00 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of SinoMab BioScience Ltd:

The MRQ is 0.0%. The data is not here.

Trends

Current period		Compared to		+/-
MRQ	-	TTM	-	0.0%
TTM	-	YOY	-1,180.3%	+1,180.3%
TTM	-	5Y	-236.1%	+236.1%
5Y	-236.1%	10Y	-196.7%	-39.3%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-	-286.1%	+286.1%
TTM	-	-224.4%	+224.4%
YOY	-1,180.3%	-288.4%	-891.9%
5Y	-236.1%	-475.2%	+239.1%
10Y	-196.7%	-624.7%	+428.0%

Measures how efficient Sinomab is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Sinomab to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Sinomab is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Sinomab is 0.0%. This means that Sinomab earned $0.00 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -286.1%.
What is the trend?
The trend is important because it shows you how Sinomab is performing over time. The most recent quarter might be important if Sinomab released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sinomab up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Sinomab

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Sinomab = -130,894
Total revenue MRQ Sinomab = 1,365
$-130,894 / $1,365 = 0.00 or 0.0%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Sinomab is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of SinoMab BioScience Ltd:

The MRQ is 0.000. The data is not here.

Trends

Current period		Compared to		+/-
MRQ	-	TTM	-	0.000
TTM	-	YOY	12.803	-12.803
TTM	-	5Y	2.561	-2.561
5Y	2.561	10Y	2.134	+0.427

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-	2.997	-2.997
TTM	-	3.247	-3.247
YOY	12.803	3.766	+9.037
5Y	2.561	5.675	-3.114
10Y	2.134	7.857	-5.723

Measures how efficient Sinomab is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Sinomab to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Sinomab is 0.0%. This means that Sinomab earned $0.00 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.00.
What is the trend?
The trend is important because it shows you how Sinomab is performing over time. The most recent quarter might be important if Sinomab released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sinomab up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Sinomab

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(943 +) \ 1,365 = 0.00

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of SinoMab BioScience Ltd.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Sinomab is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 2.39 means the company has $2.39 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of SinoMab BioScience Ltd:

The MRQ is 2.386. The company is able to pay all its short-term debts. +1
The TTM is 2.386. The company is able to pay all its short-term debts. +1

Trends

Current period		Compared to		+/-
MRQ	2.386	TTM	2.386	0.000
TTM	2.386	YOY	6.056	-3.670
TTM	2.386	5Y	7.498	-5.112
5Y	7.498	10Y	6.363	+1.135

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.386	3.930	-1.544
TTM	2.386	4.251	-1.865
YOY	6.056	5.436	+0.620
5Y	7.498	6.045	+1.453
10Y	6.363	6.363	0.000

Measures if Sinomab is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Sinomab if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Sinomab is 2.39. This means Sinomab has $2.39 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.93.
What is the trend?
The trend is important because it shows you how Sinomab is performing over time. The most recent quarter might be important if Sinomab released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sinomab up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Sinomab

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
343,523 \ 174,841) = 2.39

The current ratio measures if Sinomab is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Sinomab is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Sinomab does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Sinomab is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Sinomab is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Sinomab to the Biotechnology industry mean.
A Quick Ratio of 2.17 means the company can pay off $2.17 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of SinoMab BioScience Ltd:

The MRQ is 2.170. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 2.170. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	2.170	TTM	2.170	0.000
TTM	2.170	YOY	5.723	-3.553
TTM	2.170	5Y	7.511	-5.341
5Y	7.511	10Y	6.404	+1.108

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	2.170	3.629	-1.459
TTM	2.170	4.065	-1.895
YOY	5.723	5.397	+0.326
5Y	7.511	5.993	+1.518
10Y	6.404	6.277	+0.127

1.4. Solvency of SinoMab BioScience Ltd.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Sinomab assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Sinomab to Biotechnology industry mean.
A Debt to Asset Ratio of 0.49 means that Sinomab assets are financed with 49.5% credit (debt) and the remaining percentage (100% - 49.5%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of SinoMab BioScience Ltd:

The MRQ is 0.495. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.495. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.495	TTM	0.495	0.000
TTM	0.495	YOY	0.347	+0.148
TTM	0.495	5Y	0.356	+0.139
5Y	0.356	10Y	0.516	-0.160

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.495	0.332	+0.163
TTM	0.495	0.334	+0.161
YOY	0.347	0.268	+0.079
5Y	0.356	0.366	-0.010
10Y	0.516	0.390	+0.126

Measures how much % of Sinomab assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Sinomab than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Sinomab to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Sinomab is 0.49. This means means that Sinomab is financed with 49.5% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 393.0%.
What is the trend?
The trend is important because it shows you how Sinomab is performing over time. The most recent quarter might be important if Sinomab released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sinomab up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Sinomab has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Sinomab

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
501,251 \ 907,389 = 49.5% or 0.49.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Sinomab is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Sinomab to the Biotechnology industry mean.
A Debt to Equity ratio of 97.9% means that company has $0.98 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of SinoMab BioScience Ltd:

The MRQ is 0.979. The company is very able to pay all its debts with equity. +2
The TTM is 0.979. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.979	TTM	0.979	0.000
TTM	0.979	YOY	0.531	+0.447
TTM	0.979	5Y	0.806	+0.173
5Y	0.806	10Y	0.672	+0.134

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.979	0.381	+0.598
TTM	0.979	0.390	+0.589
YOY	0.531	0.334	+0.197
5Y	0.806	0.434	+0.372
10Y	0.672	0.466	+0.206

Measures if Sinomab is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Sinomab is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Sinomab is 0.98. This means that Sinomab can pay off $0.98 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.38.
What is the trend?
The trend is important because it shows you how Sinomab is performing over time. The most recent quarter might be important if Sinomab released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sinomab up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Sinomab

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
501,251 \ 406,138 = 0.98 or 97.9%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of SinoMab BioScience Ltd

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Sinomab generates.

Above 15 is considered overpriced but always compare Sinomab to the Biotechnology industry mean.
A PE ratio of -6.95 means the investor is paying $-6.95 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of SinoMab BioScience Ltd:

The EOD is -7.262. Based on the earnings, the company is expensive. -2
The MRQ is -6.954. Based on the earnings, the company is expensive. -2
The TTM is -6.954. Based on the earnings, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-7.262	MRQ	-6.954	-0.307
MRQ	-6.954	TTM	-6.954	0.000
TTM	-6.954	YOY	-10.834	+3.880
TTM	-6.954	5Y	-14.548	+7.594
5Y	-14.548	10Y	-12.123	-2.425

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-7.262	-2.315	-4.947
MRQ	-6.954	-2.560	-4.394
TTM	-6.954	-2.664	-4.290
YOY	-10.834	-4.122	-6.712
5Y	-14.548	-6.258	-8.290
10Y	-12.123	-6.108	-6.015

Measures how much money you pay for each share for every $1 in earnings Sinomab generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Sinomab to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Sinomab is -6.95. This means the investor is paying $-6.95 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.56.
What is the trend?
The trend is important because it shows you how Sinomab is performing over time. The most recent quarter might be important if Sinomab released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sinomab up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Sinomab

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
-67,048 \ 1,034,920 = EPS
PE ratio MRQ = -6.95

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of SinoMab BioScience Ltd:

The EOD is -4.973. Based on how much money comes from the company's main activities, the company is expensive. -2
The MRQ is -4.763. Based on how much money comes from the company's main activities, the company is expensive. -2
The TTM is -4.763. Based on how much money comes from the company's main activities, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-4.973	MRQ	-4.763	-0.211
MRQ	-4.763	TTM	-4.763	0.000
TTM	-4.763	YOY	-21.232	+16.469
TTM	-4.763	5Y	-12.417	+7.654
5Y	-12.417	10Y	-10.347	-2.069

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-4.973	-3.067	-1.906
MRQ	-4.763	-3.251	-1.512
TTM	-4.763	-3.545	-1.218
YOY	-21.232	-5.595	-15.637
5Y	-12.417	-8.315	-4.102
10Y	-10.347	-8.708	-1.639

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Sinomab is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 3.88 means the investor is paying $3.88 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of SinoMab BioScience Ltd:

The EOD is 4.049. Based on the equity, the company is fair priced.
The MRQ is 3.878. Based on the equity, the company is fair priced.
The TTM is 3.878. Based on the equity, the company is fair priced.

Trends

Current period		Compared to		+/-
EOD	4.049	MRQ	3.878	+0.171
MRQ	3.878	TTM	3.878	0.000
TTM	3.878	YOY	4.590	-0.712
TTM	3.878	5Y	3.394	+0.484
5Y	3.394	10Y	2.828	+0.566

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	4.049	1.905	+2.144
MRQ	3.878	2.111	+1.767
TTM	3.878	2.095	+1.783
YOY	4.590	2.836	+1.754
5Y	3.394	3.443	-0.049
10Y	2.828	3.794	-0.966

2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of SinoMab BioScience Ltd compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	-0.156	-0.156	0%	-0.281	+80%	0.103	-252%	0.078	-301%
Book Value Per Share	-	-	0.467	0.467	0%	0.623	-25%	0.611	-24%	0.502	-7%
Current Ratio	-	-	2.386	2.386	0%	6.056	-61%	7.498	-68%	6.363	-63%
Debt To Asset Ratio	-	-	0.495	0.495	0%	0.347	+43%	0.356	+39%	0.516	-4%
Debt To Equity Ratio	-	-	0.979	0.979	0%	0.531	+84%	0.806	+21%	0.672	+46%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	-0.260	-0.260	0%	-0.264	+1%	-0.193	-26%	-0.168	-35%
Free Cash Flow Per Share	-	-	-0.380	-0.380	0%	-0.135	-65%	-0.203	-46%	-0.176	-54%
Free Cash Flow To Equity Per Share	-	-	-0.286	-0.286	0%	-0.082	-71%	0.082	-449%	0.076	-478%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Intrinsic Value_10Y_max	-	-	-3.790	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-4.320	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	-0.242	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-0.294	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	-0.832	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-1.008	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	-1.549	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-1.855	-	-	-	-	-	-	-	-
Market Cap	2063426400.000	+4%	1976085600.000	1976085600.000	0%	3122433600.000	-37%	2797089120.000	-29%	2330907600.000	-15%
Net Profit Margin	-	-	-	-	0%	-11.122	0%	-2.224	0%	-1.854	0%
Operating Margin	-	-	-	-	0%	-11.803	0%	-2.361	0%	-1.967	0%
Operating Ratio	-	-	-	-	0%	12.803	-100%	2.561	-100%	2.134	-100%
Pb Ratio	4.049	+4%	3.878	3.878	0%	4.590	-16%	3.394	+14%	2.828	+37%
Pe Ratio	-7.262	-4%	-6.954	-6.954	0%	-10.834	+56%	-14.548	+109%	-12.123	+74%
Price Per Share	1.890	+4%	1.810	1.810	0%	2.860	-37%	2.562	-29%	2.135	-15%
Price To Free Cash Flow Ratio	-4.973	-4%	-4.763	-4.763	0%	-21.232	+346%	-12.417	+161%	-10.347	+117%
Price To Total Gains Ratio	-12.091	-4%	-11.580	-11.580	0%	-10.178	-12%	-13.229	+14%	-13.229	+14%
Quick Ratio	-	-	2.170	2.170	0%	5.723	-62%	7.511	-71%	6.404	-66%
Return On Assets	-	-	-0.282	-0.282	0%	-0.277	-2%	-0.365	+29%	-0.353	+25%
Return On Equity	-	-	-0.558	-0.558	0%	-0.424	-24%	-0.880	+58%	-0.733	+32%
Total Gains Per Share	-	-	-0.156	-0.156	0%	-0.281	+80%	0.103	-252%	0.078	-301%
Usd Book Value	-	-	65072727.500	65072727.500	0%	86864860.200	-25%	85204862.360	-24%	69919623.567	-7%
Usd Book Value Change Per Share	-	-	-0.020	-0.020	0%	-0.036	+80%	0.013	-252%	0.010	-301%
Usd Book Value Per Share	-	-	0.060	0.060	0%	0.080	-25%	0.078	-24%	0.064	-7%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	-0.033	-0.033	0%	-0.034	+1%	-0.025	-26%	-0.021	-35%
Usd Free Cash Flow	-	-	-52985156.300	-52985156.300	0%	-18779945.100	-65%	-28349170.140	-46%	-24497414.633	-54%
Usd Free Cash Flow Per Share	-	-	-0.049	-0.049	0%	-0.017	-65%	-0.026	-46%	-0.022	-54%
Usd Free Cash Flow To Equity Per Share	-	-	-0.037	-0.037	0%	-0.010	-71%	0.010	-449%	0.010	-478%
Usd Market Cap	263499551.280	+4%	252346131.120	252346131.120	0%	398734770.720	-37%	357188280.624	-29%	297656900.520	-15%
Usd Price Per Share	0.241	+4%	0.231	0.231	0%	0.365	-37%	0.327	-29%	0.273	-15%
Usd Profit	-	-	-36286976.600	-36286976.600	0%	-36802373.800	+1%	-26940715.760	-26%	-23471643.100	-35%
Usd Revenue	-	-	-	-	0%	3309090.100	-100%	661818.020	-100%	551515.017	-100%
Usd Total Gains Per Share	-	-	-0.020	-0.020	0%	-0.036	+80%	0.013	-252%	0.010	-301%
	EOD	+5 -3	MRQ	TTM	+0 -0	YOY	+10 -21	5Y	+5 -26	10Y	+6 -25

3.2. Fundamental Score

Let's check the fundamental score of SinoMab BioScience Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-7.262
Price to Book Ratio (EOD)	Between	0-1	4.049
Net Profit Margin (MRQ)	Greater than	0	0.000
Operating Margin (MRQ)	Greater than	0	0.000
Quick Ratio (MRQ)	Greater than	1	2.170
Current Ratio (MRQ)	Greater than	1	2.386
Debt to Asset Ratio (MRQ)	Less than	1	0.495
Debt to Equity Ratio (MRQ)	Less than	1	0.979
Return on Equity (MRQ)	Greater than	0.15	-0.558
Return on Assets (MRQ)	Greater than	0.05	-0.282
Total			4/10 (40.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

3.3. Technical Score

Let's check the technical score of SinoMab BioScience Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	79.519
Ma 20	Greater than	Ma 50	1.583
Ma 50	Greater than	Ma 100	1.467
Ma 100	Greater than	Ma 200	1.488
Open	Greater than	Close	1.890
Total			3/5 (60.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in HKD. All numbers in thousands.

Summary

Total Assets	1,008,348
Total Liabilities	498,773
Total Stockholder Equity	509,575

	As reported
Total Liabilities	498,773
Total Stockholder Equity	+ 509,575
Total Assets	= 1,008,348

Assets

Total Assets	1,008,348
Total Current Assets	447,093
Long-term Assets	561,255

Total Current Assets

Total Current Assets (as reported)	447,093
Cash And Cash Equivalents	345,712
Short-term Investments	30,476
Other Current Assets	12,474
Total Current Assets (calculated)	388,662
+/-	58,431

Long-term Assets

Long-term Assets (as reported)	561,255
Property Plant Equipment	556,655
Intangible Assets	2,595
Long-term Assets Other	70,838
Long-term Assets (calculated)	630,088
+/-	68,833

Liabilities & Shareholders' Equity

Total Current Liabilities	187,391
Long-term Liabilities	311,382
Total Stockholder Equity	509,575

Total Current Liabilities

Total Current Liabilities (as reported)	187,391
Short Long Term Debt	30,421
Other Current Liabilities	130,234
Total Current Liabilities (calculated)	160,655
+/-	26,736

Long-term Liabilities

Long-term Liabilities (as reported)	311,382
Long term Debt Total	311,382
Long-term Liabilities (calculated)	311,382
+/-	0

Total Stockholder Equity

Total Stockholder Equity (as reported)	509,575
Common Stock	1,725,211
Other Stockholders Equity	-1,215,636
Total Stockholder Equity (calculated)	509,575
+/-	0

Other

Capital Stock	1,725,211
Cash And Equivalents	345,712
Cash and Short Term Investments	376,188
Common Stock Shares Outstanding	1,034,920
Liabilities and Stockholders Equity	1,008,348
Net Invested Capital	778,354
Net Tangible Assets	506,980
Net Working Capital	259,702
Property Plant and Equipment Gross	592,867

Balance Sheet

Currency in HKD. All numbers in thousands.

Trend

2022-12-31

2021-12-31

2020-12-31

2019-12-31

2018-12-31

2017-12-31

> Total Assets

161,636
88,819
1,284,165
1,129,523
1,041,655
1,008,348

1,008,348

1,041,655

1,129,523

1,284,165

88,819

161,636

> Total Current Assets

126,826
50,270
1,215,042
934,354
595,685
447,093

447,093

595,685

934,354

1,215,042

50,270

126,826

Cash And Cash Equivalents

66,096
41,512
1,200,868
810,370
562,983
345,712

345,712

562,983

810,370

1,200,868

41,512

66,096

Short-term Investments

46,840
0
0
93,058
0
30,476

30,476

93,058

46,840

Net Receivables

259
0
0
0
0
0

259

Other Current Assets

0
0
6,489
12,774
26,547
12,474

12,474

26,547

12,774

6,489

> Long-term Assets

34,810
38,549
69,123
195,169
445,970
561,255

561,255

445,970

195,169

69,123

38,549

34,810

Property Plant Equipment

34,705
38,409
69,123
161,881
414,672
556,655

556,655

414,672

161,881

69,123

38,409

34,705

Intangible Assets

0
0
0
0
1,921
2,595

2,595

1,921

Other Assets

105
140
26,955
17,349
60,909
72,843

72,843

60,909

17,349

26,955

140

105

> Total Liabilities

212,588
61,413
152,249
142,512
361,429
498,773

498,773

361,429

142,512

152,249

61,413

212,588

> Total Current Liabilities

184,907
28,419
106,675
58,804
98,364
187,391

187,391

98,364

58,804

106,675

28,419

184,907

Short-term Debt

46,840
10,000
0
5,000
0
0

5,000

10,000

46,840

Short Long Term Debt

170,000
10,000
0
5,000
5,000
30,421

30,421

5,000

10,000

170,000

Other Current Liabilities

74
354
21,297
35,439
78,116
130,234

130,234

78,116

35,439

21,297

354

> Long-term Liabilities

27,681
32,994
45,574
83,708
263,065
311,382

311,382

263,065

83,708

45,574

32,994

27,681

Long term Debt Total

27,681
32,994
45,574
83,708
263,065
311,382

311,382

263,065

83,708

45,574

32,994

27,681

> Total Stockholder Equity

-50,952
27,406
1,131,916
987,011
680,226
509,575

509,575

680,226

987,011

1,131,916

27,406

-50,952

Common Stock

152,532
301,532
1,679,126
1,679,126
1,679,126
1,725,211

1,725,211

1,679,126

301,532

152,532

Retained Earnings

-1,140,032

-962,961

-692,115

-552,167

-275,885

-192,275

Capital Surplus

Treasury Stock

Other Stockholders Equity

-11,209
1,759
4,957
-692,115
-35,939
-1,215,636

-1,215,636

-35,939

-692,115

4,957

1,759

-11,209

Balance Sheet

Currency in HKD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Accumulated Other Comprehensive Income	-	-	-	-8,132	-18,579	-13,019
Capital Lease Obligations	88,404	76,682	37,377	33,332	50,267	41,980
Capital Stock	1,725,211	1,679,126	1,679,126	1,679,126	301,532	-
Cash	345,712	562,983	810,370	1,200,868	41,512	66,096
Cash And Equivalents	345,712	562,983	810,370	1,200,868	41,512	66,096
Cash And Short Term Investments	376,188	562,983	903,428	1,200,868	41,512	112,936
Common Stock	1,725,211	1,679,126	1,679,126	1,679,126	301,532	152,532
Common Stock Shares Outstanding	1,034,920	1,006,240	1,006,240	1,006,240	1,006,240	1,006,240
Common Stock Total Equity	-	-	1,679,126	1,679,126	301,532	152,532
Intangible Assets	2,595	1,921	-	-	-	-
Liabilities And Stockholders Equity	1,008,348	1,041,655	1,129,523	1,284,165	88,819	161,636
Long Term Debt	238,358	193,777	55,461	20,282	-	-
Long Term Debt Total	311,382	263,065	83,708	45,574	32,994	27,681
Net Debt	-	-	-749,909	-1,147,254	18,755	145,884
Net Invested Capital	778,354	879,003	1,047,472	1,152,198	37,406	119,048
Net Receivables	-	-	-	-	-	259
Net Tangible Assets	506,980	678,305	987,011	1,131,916	27,406	-50,952
Net Working Capital	259,702	497,321	875,550	1,108,367	21,851	-58,081
Non Current Assets Total	561,255	445,970	195,169	69,123	38,549	34,810
Non Current Liabilities Total	311,382	263,065	83,708	45,574	32,994	27,681
Non Currrent Assets Other	70,838	58,465	15,958	69,123	38,549	34,810
Other Assets	72,843	60,909	17,349	26,955	140	105
Other Current Assets	12,474	26,547	12,774	6,489	-	-
Other Current Liab	130,234	78,116	35,439	21,297	354	74
Other Stockholder Equity	-1,215,636	-35,939	-692,115	4,957	1,759	-11,209
Property Plant And Equipment Gross	592,867	435,682	145,923	42,168	38,409	34,705
Property Plant And Equipment Net	556,655	414,672	161,881	69,123	-	-
Property Plant Equipment	485,817	356,207	145,923	42,168	38,409	34,705
Retained Earnings	-1,140,032	-962,961	-692,115	-552,167	-275,885	-192,275
Short Long Term Debt	30,421	5,000	5,000	0	10,000	170,000
Short Long Term Debt Total	-	-	60,461	53,614	60,267	211,980
Short Term Debt	0	0	5,000	0	10,000	46,840
Short Term Investments	30,476	0	93,058	-	0	46,840
Total Assets	1,008,348	1,041,655	1,129,523	1,284,165	88,819	161,636
Total Current Assets	447,093	595,685	934,354	1,215,042	50,270	126,826
Total Current Liabilities	187,391	98,364	58,804	106,675	28,419	184,907
Total Liab	498,773	361,429	142,512	152,249	61,413	212,588
Total Stockholder Equity	509,575	680,226	987,011	1,131,916	27,406	-50,952

	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-04-30	2019-03-31
Accumulated Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-8,132	-20,277	-20,277
Capital Lease Obligations	68,929	-	88,404	-	71,596	-	76,682	-	77,380	-	37,377	-	32,210	-	33,332	35,390	-
Capital Stock	1,725,211	-	1,725,211	-	1,679,126	-	1,679,126	-	1,679,126	-	-	-	-	-	-	-	-
Cash	286,463	-	345,712	-	367,638	-	562,983	-	643,060	-	810,370	-	1,036,496	-	1,200,868	196,445	196,445
Cash And Equivalents	286,463	-	345,712	-	367,638	-	562,983	-	643,060	-	810,370	-	1,036,496	-	-	-	-
Cash And Short Term Investments	318,082	-	376,188	-	407,842	-	562,983	-	693,305	-	903,428	-	1,114,398	-	-	-	-
Common Stock	1,725,211	1,725,211	1,725,211	1,725,211	1,679,126	1,679,126	1,679,126	1,679,126	1,679,126	1,679,126	1,679,126	1,679,126	1,679,126	1,679,126	-	-	-
Common Stock Shares Outstanding	1,034,920	-	1,034,920	-	1,006,240	-	1,006,240	-	1,006,240	-	1,006,240	-	1,006,240	-	1,006,240	-	836,655
Common Stock Total Equity	-	-	-	-	-	-	-	-	-	-	1,679,126	-	1,679,126	-	1,679,126	500,954	500,954
Intangible Assets	2,067	-	2,595	-	1,928	-	1,921	-	248	-	-	-	-	-	-	-	-
Liabilities And Stockholders Equity	907,389	-	1,008,348	-	922,115	-	1,041,655	-	1,039,668	-	1,129,523	-	1,221,806	-	1,284,165	246,885	246,885
Long Term Debt	270,530	-	238,358	-	213,062	-	193,777	-	120,543	-	55,461	-	55,944	-	20,282	-	-
Long Term Debt Total	326,410	-	311,382	-	273,598	-	263,065	-	188,128	-	83,708	-	76,367	-	-	-	-
Net Debt	45,454	-	-	-	-	-	-	-	-	-	-749,909	-	-902,650	-	-1,147,254	-151,055	-151,055
Net Invested Capital	738,055	-	778,354	-	794,316	-	879,003	-	929,147	-	1,047,472	-	1,162,709	-	-	-	-
Net Tangible Assets	404,071	404,071	506,980	506,980	566,826	566,826	678,305	678,305	803,356	803,356	987,011	987,011	1,104,265	1,104,265	-	-	27,406
Net Working Capital	168,682	-	259,702	-	368,200	-	497,321	-	687,768	-	875,550	-	1,090,309	-	-	-	-
Non Current Assets Total	563,866	-	561,255	-	474,152	-	445,970	-	303,964	-	195,169	-	90,323	-	69,123	46,131	-
Non Current Liabilities Total	326,410	-	311,382	-	273,598	-	263,065	-	188,128	-	83,708	-	76,367	-	45,574	28,286	-
Non Currrent Assets Other	40,282	-	70,838	-	72,944	-	58,465	-	38,382	-	15,958	-	31,971	-	-	46,131	-
Other Assets	41,509	41,509	72,843	72,843	75,421	75,421	60,909	60,909	40,839	40,839	17,349	17,349	31,971	31,971	-	-	-
Other Current Assets	12,474	12,474	12,474	12,474	-	-	-	-	20,982	20,982	-	-	-	-	-	-	-
Other Current Liab	100,405	100,405	130,234	130,234	56,203	56,203	78,116	78,116	33,141	33,141	35,439	35,439	26,887	26,887	-	-	-
Other Stockholder Equity	62,142	62,142	-1,215,636	-1,215,636	-3,621	-3,621	-35,939	-35,939	-86,352	-86,352	-692,115	-17,348	58,146	58,146	-	-	-
Property Plant And Equipment Gross	520,290	-	592,867	-	-	-	-	-	-	-	145,923	-	58,352	-	42,168	41,182	41,182
Property Plant And Equipment Net	520,290	-	556,655	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Property Plant Equipment	520,290	520,290	485,817	485,817	371,724	371,724	356,207	356,207	232,955	232,955	145,923	145,923	58,352	58,352	-	-	-
Retained Earnings	-1,381,215	-1,381,215	-1,140,032	-	-1,106,751	-1,106,751	-962,961	-962,961	-789,170	-789,170	-692,115	-674,767	-633,007	-633,007	-	-	-
Short Long Term Debt	61,387	-	30,421	-	12,500	-	5,000	-	5,000	-	5,000	-	2,500	-	0	10,000	-
Short Long Term Debt Total	-	-	-	-	-	-	-	-	188,128	-	60,461	-	133,846	-	53,614	45,390	45,390
Short Term Debt	0	-	0	-	0	-	0	-	0	-	5,000	-	77,902	-	-	10,000	-
Short Term Investments	31,619	-	30,476	-	40,204	-	0	-	50,245	-	93,058	-	77,902	-	-	-	-
Total Assets	907,389	-	1,008,348	-	922,115	-	1,041,655	-	1,039,668	-	1,129,523	-	1,221,806	-	1,284,165	246,885	246,885
Total Current Assets	343,523	343,523	447,093	447,093	447,963	447,963	595,685	595,685	735,704	735,704	934,354	934,354	1,131,483	1,131,483	1,215,042	200,754	200,754
Total Current Liabilities	174,841	174,841	187,391	187,391	79,763	79,763	98,364	98,364	47,936	47,936	58,804	58,804	41,174	41,174	106,675	21,206	21,206
Total Liab	501,251	-	498,773	-	353,361	-	361,429	-	236,064	-	142,512	-	117,541	-	152,249	49,492	49,492
Total Stockholder Equity	406,138	-	509,575	-	568,754	-	680,226	-	803,604	-	987,011	-	1,104,265	-	1,131,916	197,393	-

Cash Flow

Currency in HKD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Begin Period Cash Flow	562,983	810,370	1,200,868	41,512	66,096	8,408
Capital Expenditures	33,400	198,232	75,955	42,286	2,746	823
Change In Cash	-220,096	-247,387	-390,498	1,159,356	-24,584	57,688
Change In Working Capital	-13,692	-147,063	-141,338	42,959	5,781	-14,157
Change To Liabilities	-12,400	33,998	-21,081	46,432	558	-2,076
Change To Netincome	6,820	73,834	9,813	2,345	25,658	17,013
Change To Operating Activities	-10,800	12,644	-18,143	-3,473	5,223	-12,081
Depreciation	27,031	20,320	10,673	8,489	5,342	4,918
End Period Cash Flow	342,887	562,983	810,370	1,200,868	41,512	66,096
Free Cash Flow	-414,919	-147,063	-233,659	-264,775	-49,575	-41,023
Investments	-112,700	75,873	-86,897	-42,286	21,466	10,315
Issuance Of Capital Stock	46,085	59,673	0	1,437,460	150,000	-
Net Borrowings	46,100	121,880	33,893	-3,886	-160,184	150,000
Net Income	-284,158	-288,194	-122,600	-276,282	-83,610	-47,974
Other Cashflows From Financing Activities	-10,615	-4,692	-52,701	-42,286	8,637	-60,000
Other Cashflows From Investing Activities	-2,058	1,344	1,344	-18	1,855	2,097
Other Non Cash Items	-4,620	-8,739	-14,930	-655	2,914	2,922
Sale Purchase Of Stock	46,085	-59,673	0	1,428,711	148,909	35
Stock Based Compensation	5,017	62,897	34,903	-	-	-
Total Cash From Financing Activities	102,285	57,515	-18,808	1,420,802	-3,555	89,035
Total Cash From Operating Activities	-300,538	-147,063	-141,338	-222,489	-46,829	-40,200
Total Cashflows From Investing Activities	-81,358	-137,702	-179,218	-42,286	21,466	10,315

	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-06-30	2019-03-31	2018-12-31	2018-06-30	2018-03-31	2017-12-31	2017-06-30	2017-03-31	2016-12-31
Begin Period Cash Flow	-	-	-	-	-	-	-	-	-	-	-	-	-	-	300,217	10,378	10,378	10,378	16,524	16,524	16,524	2,102	2,102	2,102
Capital Expenditures	30,627	30,627	47,036	47,036	30,336	30,336	65,347	65,347	33,770	33,770	33,910	33,910	4,068	4,068	42,286	10,572	10,572	10,572	687	687	687	206	206	206
Change In Cash	-31,751	-31,751	-12,250	-12,250	-97,798	-97,798	-40,039	-40,039	-83,655	-83,655	156,737	156,737	-351,986	-351,986	1,159,356	289,839	289,839	289,839	-6,146	-6,146	-6,146	14,422	14,422	14,422
Change In Working Capital	-62,750	-	-300,538	-	-145,587	-	-147,063	-	-88,857	-	-141,338	-	-19,879	-	45,952	10,740	10,740	10,740	1,445	1,445	1,445	-3,539	-3,539	-3,539
Change To Liabilities	0	0	-6,200	-6,200	0	0	16,999	16,999	0	0	1,707	1,707	-12,248	-12,248	-	4,145	4,145	-	-	-	-	-	-	-
Change To Netincome	35,673	35,673	4,309	4,309	-899	-899	24,144	24,144	12,773	12,773	-10,016	-10,016	14,922	14,922	-	656	656	-	-	-	-	-	-	-
Change To Operating Activities	-	-	-5,400	-5,400	-	-	6,322	6,322	6,322	6,322	-7,616	-7,616	-1,456	-1,456	-	2,892	2,892	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	10,160	10,160	10,160	10,160	3,098	3,098	2,239	2,239	8,489	2,122	2,122	2,122	1,336	1,336	1,336	1,230	1,230	1,230
End Period Cash Flow	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	300,217	300,217	300,217	10,378	10,378	10,378	16,524	16,524	16,524
Free Cash Flow	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-66,194	-66,194	-66,194	-12,394	-12,394	-12,394	-10,256	-10,256	-10,256
Investments	-	-	-36,471	-36,471	-19,879	-19,879	25,000	25,000	12,937	12,937	261,134	261,134	-304,583	-304,583	-	-	-	-	-	-	-	-	-	-
Net Borrowings	22,640	22,640	12,215	12,215	10,835	10,835	33,438	33,438	27,503	27,503	-1,702	-1,702	18,648	18,648	-	-12,030	-12,030	-	-	-	-	-	-	-
Net Income	-67,048	-67,048	-70,184	-70,184	-71,895	-71,895	-86,896	-86,896	-57,202	-57,202	-20,880	-20,880	-40,420	-40,420	-276,282	-69,071	-69,071	-69,071	-20,903	-20,903	-20,903	-11,994	-11,994	-11,994
Other Cashflows From Financing Activities	-1,618	-1,618	-4,925	-4,925	-383	-383	-757	-757	-1,589	-1,589	-1,296	-1,296	-25,055	-25,055	-4,023	-2,120	-2,120	-	2,159	2,159	2,159	-15,000	-15,000	-15,000
Other Cashflows From Investing Activities	-313	-313	-558	-558	-472	-472	10,948	10,948	-10,276	-10,276	-10,276	-10,276	-9	-9	-	-	-	-	-	-	-	-	-	-
Other Non Cash Items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-164	-164	-164	729	729	729	731	731	731
Sale Purchase Of Stock	-	-	46,085	-	0	-	-59,673	-	-59,673	-	0	-	-49,253	-	1,428,711	198,069	-	-	-	-	-	-	-	-
Total Cash From Financing Activities	21,022	21,022	40,690	40,690	10,453	10,453	32,681	32,681	-3,923	-3,923	-2,997	-2,997	-6,407	-6,407	1,420,802	171,700	-	-	-	-	-	-	-	-
Total Cash From Operating Activities	-31,375	-31,375	-77,476	-77,476	-72,794	-72,794	-29,103	-29,103	-44,429	-44,429	-33,707	-33,707	-36,962	-36,962	-222,489	-55,622	-55,622	-55,622	-11,707	-11,707	-11,707	-10,050	-10,050	-10,050
Total Cashflows From Investing Activities	-30,971	-30,971	10,165	10,165	-50,844	-50,844	-37,596	-37,596	-31,256	-31,256	227,224	227,224	-316,833	-316,833	-42,286	-10,892	-10,892	-	-	-	-	-	-	-

Income Statement

Currency in HKD. All numbers in thousands.

	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31
Cost Of Revenue	-	-	-	-	743	117
Depreciation And Amortization	-	-	-	8,489	1,714	1,252
Ebit	-258,927	-305,856	-122,600	-275,886	-54,799	-39,595
Ebitda	-251,163	-282,373	-120,184	-267,397	-53,085	-38,343
Gross Profit	-	-	-	-	-743	-117
Income Before Tax	-284,158	-288,194	-122,600	-276,282	-83,610	-51,901
Interest Expense	31,935	5,821	2,416	2,338	3,030	0
Interest Income	10,358	16,731	17,346	319	28,194	12,290
Minority Interest	-	-	-	0	0	3,927
Net Income	-284,158	-288,194	-122,600	-276,282	-83,610	-47,974
Net Income Applicable To Common Shares	-284,158	-288,194	-122,600	-276,282	-83,610	-47,974
Net Income From Continuing Ops	-284,158	-288,194	-122,600	-276,282	-83,610	-51,901
Net Interest Income	4,620	10,910	14,930	655	-2,914	-2,922
Operating Income	-273,800	-305,856	-162,652	-275,886	-54,799	-39,595
Other Operating Expenses	-	-	162,652	275,886	54,799	39,595
Reconciled Depreciation	28,033	20,655	10,673	8,489	5,342	4,918
Research Development	180,368	199,113	103,402	214,342	47,283	32,603
Selling General Administrative	82,591	133,400	72,010	61,544	2,014	991
Tax Provision	0	0	0	0	0	0
Total Operating Expenses	258,927	331,769	162,652	275,886	54,799	39,595
Total Other Income Expense Net	-	-	-	-	-27,331	-12,306
Total Revenue	0	25,913	0	0	0	0

	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-06-30	2019-03-31	2018-12-31	2018-06-30	2018-03-31	2017-12-31	2017-06-30	2017-03-31	2016-12-31
Cost Of Revenue	943	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation And Amortization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,122	2,122	2,122	429	429	429	313	313	313
Ebit	-54,712	-54,712	-71,474	-71,474	-57,990	-57,990	-91,507	-91,507	-61,422	-61,422	-35,695	-35,695	-45,632	-45,632	-	-68,972	-68,972	-68,972	-13,700	-13,700	-13,700	-9,899	-9,899	-9,899
Ebitda	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-66,849	-66,849	-66,849	-13,271	-13,271	-13,271	-9,586	-9,586	-9,586
Gross Profit	422	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Before Tax	-134,096	-	-140,368	-	-143,790	-	-173,791	-	-114,403	-	-41,760	-	-80,840	-	-229,936	-69,071	-69,071	-69,071	-20,903	-20,903	-20,903	-12,975	-12,975	-12,975
Interest Expense	19,974	-	32,348	-	29,546	-	-	-	-	-	-	-	-	-	-	585	585	585	758	758	758	740	740	740
Interest Income	3,202	-	5,027	-	5,331	-	5,943	-	4,167	-	1,639	-	1,524	-	1,033	1,305	-	-	-	-	-	-	-	-
Net Income	-134,096	-	-140,368	-	-143,790	-	-173,791	-	-114,403	-	-41,760	-	-80,840	-	-229,936	-69,071	-69,071	-69,071	-20,903	-20,903	-20,903	-11,994	-11,994	-11,994
Net Income Applicable To Common Shares	-67,048	-67,048	-70,184	-70,184	-71,895	-71,895	-86,896	-86,896	-57,202	-57,202	-20,880	-20,880	-40,420	-40,420	-229,936	-23,173	-23,173	-	-	-	-	-	-	-
Operating Income	-130,894	-	-135,341	-	-138,459	-	-167,848	-	-110,236	-	-40,121	-	-79,316	-	-228,903	-68,972	-68,972	-68,972	-13,700	-13,700	-13,700	-9,899	-9,899	-9,899
Other Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	68,972	68,972	68,972	13,700	13,700	13,700	9,899	9,899	9,899
Reconciled Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,122	2,122	2,122	429	429	429	313	313	313
Research Development	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53,586	53,586	53,586	11,821	11,821	11,821	8,151	8,151	8,151
Selling General Administrative	50,200	-	48,742	-	33,849	-	100,539	-	32,861	-	21,980	-	50,030	-	49,525	15,386	15,386	15,386	504	504	504	248	248	248
Tax Provision	0	-	0	-	0	-	0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	1,365	-	0	-	0	-	25,913	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-

Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue	0
Cost of Revenue	--
Gross Profit	-	0

Operating Income (+$)
Gross Profit	-
Operating Expense	-258,927
Operating Income	-273,800	-258,927

Operating Expense (+$)
Research Development	180,368
Selling General Administrative	82,591
Selling And Marketing Expenses	-
Operating Expense	258,927	262,959

Net Interest Income (+$)
Interest Income	10,358
Interest Expense	-31,935
Other Finance Cost	-26,197
Net Interest Income	4,620

Pretax Income (+$)
Operating Income	-273,800
Net Interest Income	4,620
Other Non-Operating Income Expenses	-
Income Before Tax (EBT)	-284,158	-273,800 EBIT - interestExpense = -290,862 -284,158 -252,223
Interest Expense	31,935
Earnings Before Interest and Taxes (EBIT)	-258,927	-252,223
Earnings Before Interest and Taxes (EBITDA)	-251,163

After tax Income (+$)
Income Before Tax	-284,158
Tax Provision	-0
Net Income From Continuing Ops	-284,158	-284,158
Net Income	-284,158
Net Income Applicable To Common Shares	-284,158

Non-recurring Events
Discontinued Operations	-
Extraordinary Items	-
Effect of Accounting Charges	-
Other Items	-
Non Recurring	-
Other Operating Expenses	-
Total Other Income/Expenses Net	-	-4,620

Technical Analysis of Sinomab
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sinomab. The general trend of Sinomab is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sinomab's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (85.7%)		Bearish trend (-85.7%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of SinoMab BioScience Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.9 < 1.9 < 1.91.

The bearish price targets are: 1.89 > 1.85 > 1.81.

Tweet this

SinoMab BioScience Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of SinoMab BioScience Ltd. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

MA 20 trending up: The MA 20 is trending up. +1
Close > MA 20: The price is above the MA 20. +1
MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
MA 50 trending up: The MA 50 is trending up. +1
Close > MA 50: The price is above the MA 50. +1
MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
MA 100 trending up: The MA 100 is trending up. +1
Close > MA 100: The price is above the MA 100. +1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending up: The MA 200 is trending up. +1
Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

SinoMab BioScience Ltd Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of SinoMab BioScience Ltd. The current macd is 0.11198929.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sinomab price going up in the near term. +2
MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Sinomab. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Sinomab price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1

SinoMab BioScience Ltd Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of SinoMab BioScience Ltd. The current adx is 53.73.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Sinomab shares, leading to potential upward momentum in its price. +1
PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.

SinoMab BioScience Ltd Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of SinoMab BioScience Ltd. The current sar is 1.59365323.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1

SinoMab BioScience Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of SinoMab BioScience Ltd. The current rsi is 79.52. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
Trending down: The RSI is trending down. -1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

SinoMab BioScience Ltd Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of SinoMab BioScience Ltd. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
STOCH > 80: The STOCH %K is above 80 and overbought. +2
STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sinomab price going down in the near term. -2
Trending down: The STOCH %K is trending down. -1

SinoMab BioScience Ltd Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of SinoMab BioScience Ltd. The current cci is 149.81.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1

SinoMab BioScience Ltd Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of SinoMab BioScience Ltd. The current cmo is 71.02.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1

SinoMab BioScience Ltd Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of SinoMab BioScience Ltd. The current willr is -5.66037736.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1

SinoMab BioScience Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of SinoMab BioScience Ltd.

SinoMab BioScience Ltd Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of SinoMab BioScience Ltd. The current atr is 0.08390991.

SinoMab BioScience Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of SinoMab BioScience Ltd. The current obv is -11,146,700.

SinoMab BioScience Ltd Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of SinoMab BioScience Ltd. The current mfi is 98.43.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

MFI > 50: +1
MFI > 80: +1

SinoMab BioScience Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for SinoMab BioScience Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-11-20	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-11-21	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-11-22	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-11-23	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-11-27	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-11-28	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-01	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-04	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-06	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-07	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-08	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-12	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-13	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-14	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-15	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2023-12-19	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	MFI	SHORT ENTRY	LONG CLOSE	80 crossover to downside
2023-12-21	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-22	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-27	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2023-12-28	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-29	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
2024-01-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-03	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-16	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-17	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-01-18	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-19	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-23	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-01-25	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-26	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-29	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-01-31	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-14	STOCH	LONG EXIT		The %K line crosses below the %D line.
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-15	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-16	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
2024-02-21	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-22	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-26	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-27	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-02-28	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-01	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-05	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-13	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-14	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-03-15	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-18	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-20	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-03-25	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-27	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	MFI	LONG ENTRY	SHORT CLOSE	80 crossover to upside
2024-04-05	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-10	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-11	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-12	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-04-15	STOCH	LONG EXIT		The %K line crosses below the %D line.
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).

6.3. Candlestick Patterns

SinoMab BioScience Ltd Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of SinoMab BioScience Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	79.519
Ma 20	Greater than	Ma 50	1.583
Ma 50	Greater than	Ma 100	1.467
Ma 100	Greater than	Ma 200	1.488
Open	Greater than	Close	1.890
Total			3/5 (60.0%)

Create your own Symbol Scanner

Get notifications about SinoMab BioScience Ltd

I send you an email if I find something interesting about SinoMab BioScience Ltd.

SinoMab BioScience Ltd Buy, Hold or Sell?

Let's analyse Sinomab together

Get notifications about SinoMab BioScience Ltd

Quick analysis of Sinomab (30 sec.)

What can you expect buying and holding a share of Sinomab? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Sinomab (5 min.)

HK$1.89

HK$0.47

HK$-4.32 - HK$-3.79

HK$-3.85 - HK$-3.32

2. Growth of Sinomab (5 min.)

Is Sinomab growing?

How much money is Sinomab making?

How much money comes from the company's main activities?

3. Financial Health of Sinomab (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Sinomab? (5 min.)

What can you expect buying and holding a share of Sinomab?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Sinomab

About SinoMab BioScience Ltd

Financial Health

Valuation

1.1. Profitability of SinoMab BioScience Ltd.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of SinoMab BioScience Ltd.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of SinoMab BioScience Ltd.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of SinoMab BioScience Ltd.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of SinoMab BioScience Ltd

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

SinoMab BioScience Ltd
Buy, Hold or Sell?